Pure Global AI
NCT06339060Not yet recruiting

An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).

An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer vs Cross Therapy.
Ruijin HospitalPhase 3ClinicalTrials.govcombination product
Verified
Study focus
Disease/Condition
Esophageal Cancer
Drug/Device/Intervention
Experimental: Arm 1 Organ preservation
Study type
Interventional
Intervention type
combination product
Sponsor & location
Primary sponsor
Ruijin Hospital
Timeline & enrollment
Phase
Phase 3
Start date
May 01, 2024
End date
Mar 01, 2028
Enrollment
356 participants
Primary outcome

3-year overall survival rate

Summary

Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to
 receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation
 strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control
 group).
 
 The 3-year overall survival rate is the primary outcome.

ICD-10 classifications
Carcinoma in situ: OesophagusMalignant neoplasm of oesophagusMalignant neoplasm: Middle third of oesophagusMalignant neoplasm: Overlapping lesion of oesophagusMalignant neoplasm: Upper third of oesophagus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06339060
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06339060 through Pure Global AI's free database. This Phase 3 trial is sponsored by Ruijin Hospital and is currently Not yet recruiting. The study focuses on Esophageal Cancer. Target enrollment is 356 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.